{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T07:33:22Z","timestamp":1778657602065,"version":"3.51.4"},"reference-count":19,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2006,4,28]],"date-time":"2006-04-28T00:00:00Z","timestamp":1146182400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2006,5]]},"abstract":"<jats:sec><jats:title>Summary<\/jats:title><\/jats:sec><jats:sec><jats:title>Background<\/jats:title><jats:p>Alicaforsen is an antisense oligonucleotide inhibitor of intercellular adhesion molecule 1 protein expression with activity in subjects with ulcerative colitis and pouchitis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>To compare the effects of alicaforsen enema to standard of care mesalazine (mesalamine) enema in subjects with mild to moderate active left\u2010sided ulcerative colitis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>A randomized, double\u2010blind, active\u2010controlled multicentre clinical trial. Subjects received a nightly enema of 120\u2003mg alicaforsen (<jats:italic>n<\/jats:italic>\u2003=\u200355), 240\u2003mg alicaforsen (<jats:italic>n<\/jats:italic>\u2003=\u200350), or 4\u2003g mesalazine (<jats:italic>n<\/jats:italic>\u2003=\u200354) for 6\u2003weeks, followed by a 24\u2010week monitoring period. The primary end point was Disease Activity Index at week 6. Clinical improvement, remission and relapse were secondary end points.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>No significant difference was observed between treatment arms in the primary end point. However, the median duration of response to alicaforsen enema treatment was two\u2010 to threefold longer (128 and 146\u2003days) in comparison with mesalazine (54\u2003days). Complete mucosal healing occurred in 24% of the 240\u2003mg alicaforsen group, when compared with 17% in the mesalazine.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Alicaforsen enema demonstrated an acute response and safety profile similar to mesalazine enema, but was differentiated by a more durable response. The extended length of remission suggests that alicaforsen enema treatment may have a disease modifying effect.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1365-2036.2006.02837.x","type":"journal-article","created":{"date-parts":[[2006,4,29]],"date-time":"2006-04-29T03:45:13Z","timestamp":1146282313000},"page":"1403-1413","source":"Crossref","is-referenced-by-count":91,"title":["Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left\u2010sided ulcerative colitis: a randomized, double\u2010blind, active\u2010controlled trial"],"prefix":"10.1111","volume":"23","author":[{"suffix":"JR","given":"P. B.","family":"MINER","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. K.","family":"WEDEL","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"XIA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B. F.","family":"BAKER","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,4,28]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.02.071"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2000.01940.x"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2001.01102.x"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.144.12.4579"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.147.9.2913"},{"key":"e_1_2_6_7_2","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/S0022-3565(24)36471-7","article-title":"An ICAM\u20101 antisense oligonucleotide prevents and reverses dextran sulfate sodium\u2010induced colitis in mice","volume":"280","author":"Bennett CF","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.med.55.091902.104408"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2003.036160"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2004.01863.x"},{"key":"e_1_2_6_11_2","first-page":"1188","article-title":"Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group","volume":"88","author":"Hanauer S","year":"1993","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198712243172603"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa042982"},{"key":"e_1_2_6_14_2","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.4049\/jimmunol.152.7.3530","article-title":"Inhibition of endothelial cell\u2010leukocyte adhesion molecule expression with antisense oligonucleotides","volume":"152","author":"Bennett CF","year":"1994","journal-title":"J Immunol"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M311683200"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(98)70418-4"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00423.2004"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.2000.01296.x"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1080\/01913120252959290"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2006.02909.x"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2006.02837.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2006.02837.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T19:10:32Z","timestamp":1736363432000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2006.02837.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4,28]]},"references-count":19,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2006,5]]}},"alternative-id":["10.1111\/j.1365-2036.2006.02837.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2006.02837.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,4,28]]}}}